Tags

Type your tag names separated by a space and hit enter

Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
Climacteric. 2008 Apr; 11(2):155-65.C

Abstract

OBJECTIVE

Estrogen agonist compounds may exert cardioprotective activity by modulating adipocytokine concentration and apoptosis. The objective of this study was to evaluate the effects of hormone therapy, tibolone and raloxifene on the serum adipocytokines resistin and adiponectin as well as on circulating markers of receptor-mediated apoptosis. Design Randomized, open-label, intervention study in the Menopause Clinic of a University Hospital.

METHODS

One hundred healthy postmenopausal women were randomized to the following groups: conjugated equine estrogens 0.625 mg (CEE) (n = 16); 17 beta-estradiol 1 mg plus norethisterone acetate 0.5 mg (E(2)/NETA) (n = 15); tibolone 2.5 mg (n = 18); raloxifene HCl 60 mg (n = 20); and no treatment (n = 19). Eighty-eight women completed the 3-month study period. Main outcome measures were levels of serum adiponectin, resistin, soluble Fas and Fas ligand.

RESULTS

Levels of serum adiponectin decreased significantly in the tibolone group (baseline: 10 556.7 +/- 4213.5 ng/ml; 3 months: 7856.3 +/- 3450.7 ng/ml; p = 0.0001) and increased in the CEE group (baseline: 9268.1 +/- 5158 ng/ml; 3 months: 11 302.6 +/- 4980.9 ng/ml; p = 0.01). Serum resistin values increased only in the tibolone group (baseline: 2.81 +/- 0.89 ng/ml; 3 months: 3.55 +/- 1.31 ng/ml; p = 0.04), while the level of Fas ligand decreased significantly in the E2/NETA (baseline: 70.4 +/- 21.9 pg/ml; 3 months: 62.1 +/- 18.6 pg/ml; p = 0.02) and tibolone group (baseline: 68.2 +/- 25.7 pg/ml; 3 months: 59.2 +/- 21.7 pg/ml; p = 0.01).

CONCLUSIONS

Of the regimens investigated, only unopposed estrogens may exert an atheroprotective effect through the increase of adiponectin and a resultant favorable lipid and anti-inflammatory profile.

Authors+Show Affiliations

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Athens.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18365858

Citation

Christodoulakos, G E., et al. "Circulating Levels of Atherogenesis-associated Adipocytokines and Apoptotic Markers Are Differentially Influenced By Hormone Therapy, Tibolone and Raloxifene in Healthy Postmenopausal Women." Climacteric : the Journal of the International Menopause Society, vol. 11, no. 2, 2008, pp. 155-65.
Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, et al. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric. 2008;11(2):155-65.
Christodoulakos, G. E., Lambrinoudaki, I. V., Creatsa, M. G., Economou, E. V., Siasou, Z., Panoulis, C. P., Kalligerou, I., & Papadias, C. (2008). Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric : the Journal of the International Menopause Society, 11(2), 155-65. https://doi.org/10.1080/13697130801954484
Christodoulakos GE, et al. Circulating Levels of Atherogenesis-associated Adipocytokines and Apoptotic Markers Are Differentially Influenced By Hormone Therapy, Tibolone and Raloxifene in Healthy Postmenopausal Women. Climacteric. 2008;11(2):155-65. PubMed PMID: 18365858.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. AU - Christodoulakos,G E, AU - Lambrinoudaki,I V, AU - Creatsa,M G, AU - Economou,E V, AU - Siasou,Z, AU - Panoulis,C P, AU - Kalligerou,I, AU - Papadias,C, PY - 2008/3/28/pubmed PY - 2008/7/1/medline PY - 2008/3/28/entrez SP - 155 EP - 65 JF - Climacteric : the journal of the International Menopause Society JO - Climacteric VL - 11 IS - 2 N2 - OBJECTIVE: Estrogen agonist compounds may exert cardioprotective activity by modulating adipocytokine concentration and apoptosis. The objective of this study was to evaluate the effects of hormone therapy, tibolone and raloxifene on the serum adipocytokines resistin and adiponectin as well as on circulating markers of receptor-mediated apoptosis. Design Randomized, open-label, intervention study in the Menopause Clinic of a University Hospital. METHODS: One hundred healthy postmenopausal women were randomized to the following groups: conjugated equine estrogens 0.625 mg (CEE) (n = 16); 17 beta-estradiol 1 mg plus norethisterone acetate 0.5 mg (E(2)/NETA) (n = 15); tibolone 2.5 mg (n = 18); raloxifene HCl 60 mg (n = 20); and no treatment (n = 19). Eighty-eight women completed the 3-month study period. Main outcome measures were levels of serum adiponectin, resistin, soluble Fas and Fas ligand. RESULTS: Levels of serum adiponectin decreased significantly in the tibolone group (baseline: 10 556.7 +/- 4213.5 ng/ml; 3 months: 7856.3 +/- 3450.7 ng/ml; p = 0.0001) and increased in the CEE group (baseline: 9268.1 +/- 5158 ng/ml; 3 months: 11 302.6 +/- 4980.9 ng/ml; p = 0.01). Serum resistin values increased only in the tibolone group (baseline: 2.81 +/- 0.89 ng/ml; 3 months: 3.55 +/- 1.31 ng/ml; p = 0.04), while the level of Fas ligand decreased significantly in the E2/NETA (baseline: 70.4 +/- 21.9 pg/ml; 3 months: 62.1 +/- 18.6 pg/ml; p = 0.02) and tibolone group (baseline: 68.2 +/- 25.7 pg/ml; 3 months: 59.2 +/- 21.7 pg/ml; p = 0.01). CONCLUSIONS: Of the regimens investigated, only unopposed estrogens may exert an atheroprotective effect through the increase of adiponectin and a resultant favorable lipid and anti-inflammatory profile. SN - 1369-7137 UR - https://www.unboundmedicine.com/medline/citation/18365858/Circulating_levels_of_atherogenesis_associated_adipocytokines_and_apoptotic_markers_are_differentially_influenced_by_hormone_therapy_tibolone_and_raloxifene_in_healthy_postmenopausal_women_ L2 - https://www.tandfonline.com/doi/full/10.1080/13697130801954484 DB - PRIME DP - Unbound Medicine ER -